Literature DB >> 32282899

Extinction of all infectious HIV in cell culture by the CRISPR-Cas12a system with only a single crRNA.

Zongliang Gao1, Minghui Fan1, Atze T Das1, Elena Herrera-Carrillo1, Ben Berkhout1,2.   

Abstract

The CRISPR-Cas9 system has been used for genome editing of various organisms. We reported inhibition of the human immunodeficiency virus (HIV) in cell culture infections with a single guide RNA (gRNA) and subsequent viral escape, but complete inactivation of infectious HIV with certain combinations of two gRNAs. The new RNA-guided endonuclease system CRISPR-Cas12a (formerly Cpf1) may provide a more promising tool for genome engineering with increased activity and specificity. We compared Cas12a to the original Cas9 system for inactivation of the integrated HIV DNA genome. Superior antiviral activity is reported for Cas12a, which can achieve full HIV inactivation with only a single gRNA (called crRNA). We propose that the different architecture of Cas9 versus Cas12a endonuclease explains this effect. We also disclose that DNA cleavage by the Cas12a endonuclease and subsequent DNA repair causes mutations with a sequence profile that is distinct from that of Cas9. Both CRISPR systems can induce the typical small deletions around the site of DNA cleavage and subsequent repair, but Cas12a does not induce the pure DNA insertions that are routinely observed for Cas9. Although these typical signatures are apparent in many literature studies, this is the first report that documents these striking differences.
© The Author(s) 2020. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Year:  2020        PMID: 32282899     DOI: 10.1093/nar/gkaa226

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  19 in total

Review 1.  Pathways Toward a Functional HIV-1 Cure: Balancing Promise and Perils of CRISPR Therapy.

Authors:  Jonathan Herskovitz; Mahmudul Hasan; Milankumar Patel; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  Methods Mol Biol       Date:  2022

Review 2.  Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics.

Authors:  Wenyi Liu; Luoxi Li; Jianxin Jiang; Min Wu; Ping Lin
Journal:  Precis Clin Med       Date:  2021-07-10

Review 3.  CRISPR/Cas technology as a promising weapon to combat viral infections.

Authors:  Carmen Escalona-Noguero; María López-Valls; Begoña Sot
Journal:  Bioessays       Date:  2021-02-11       Impact factor: 4.345

4.  SpCas9- and LbCas12a-Mediated DNA Editing Produce Different Gene Knockout Outcomes in Zebrafish Embryos.

Authors:  Darya A Meshalkina; Aleksei S Glushchenko; Elana V Kysil; Igor V Mizgirev; Andrej Frolov
Journal:  Genes (Basel)       Date:  2020-07-03       Impact factor: 4.096

Review 5.  Designer nucleases to treat malignant cancers driven by viral oncogenes.

Authors:  Tristan A Scott; Kevin V Morris
Journal:  Virol J       Date:  2021-01-13       Impact factor: 4.099

6.  Transient CRISPR-Cas Treatment Can Prevent Reactivation of HIV-1 Replication in a Latently Infected T-Cell Line.

Authors:  Ye Liu; Rienk E Jeeninga; Bep Klaver; Ben Berkhout; Atze T Das
Journal:  Viruses       Date:  2021-12-08       Impact factor: 5.048

7.  CRISPR-Cas9 Mediated Exonic Disruption for HIV-1 Elimination.

Authors:  Jonathan Herskovitz; Mahmudul Hasan; Milankumar Patel; Wilson R Blomberg; Jacob D Cohen; Jatin Machhi; Farah Shahjin; R Lee Mosley; JoEllyn McMillan; Bhavesh D Kevadiya; Howard E Gendelman
Journal:  EBioMedicine       Date:  2021-11-10       Impact factor: 8.143

8.  Multiplexed tat-Targeting CRISPR-Cas9 Protects T Cells from Acute HIV-1 Infection with Inhibition of Viral Escape.

Authors:  Youdiil Ophinni; Sayaka Miki; Yoshitake Hayashi; Masanori Kameoka
Journal:  Viruses       Date:  2020-10-28       Impact factor: 5.048

Review 9.  Novel CRISPR-Cas Systems: An Updated Review of the Current Achievements, Applications, and Future Research Perspectives.

Authors:  Sweta Nidhi; Uttpal Anand; Patrik Oleksak; Pooja Tripathi; Jonathan A Lal; George Thomas; Kamil Kuca; Vijay Tripathi
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

Review 10.  Genome Editing Technologies as Cellular Defense Against Viral Pathogens.

Authors:  Yingzi Zhang; Mo Li
Journal:  Front Cell Dev Biol       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.